|
March 29, 2006 Categories: Uncategorized Posted by admin
Boston Scientific Corporation (NYSE: BSX – News) welcomed recent results from studies presented at the annual American College of Cardiology Scientific Session in Atlanta, March 11- 14. Several clinical trials and registries offered data that indicated a positive numerical trend in the performance of the TAXUS® Express2(TM) paclitaxel-eluting stent system when used in complex patients. Studies ranged from larger, real-world registries to smaller clinical trials and compared the TAXUS Express2 stent system to bare-metal stent control groups and to competitive drug-eluting stent systems.
Full press releases
|
|
